ICCC vs. AWH, ABIO, OCX, CDIO, VNRX, TRIB, BMRA, TKNO, QNCX, and JUPW
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Aspira Women's Health (AWH), ARCA biopharma (ABIO), OncoCyte (OCX), Cardio Diagnostics (CDIO), VolitionRx (VNRX), Trinity Biotech (TRIB), Biomerica (BMRA), Alpha Teknova (TKNO), Quince Therapeutics (QNCX), and Jupiter Wellness (JUPW). These companies are all part of the "medical" sector.
Aspira Women's Health (NASDAQ:AWH) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings.
In the previous week, Aspira Women's Health had 1 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for Aspira Women's Health and 3 mentions for ImmuCell. Aspira Women's Health's average media sentiment score of 1.59 beat ImmuCell's score of -0.27 indicating that ImmuCell is being referred to more favorably in the news media.
Aspira Women's Health has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
12.2% of Aspira Women's Health shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 4.3% of Aspira Women's Health shares are owned by insiders. Comparatively, 6.6% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aspira Women's Health currently has a consensus price target of $4.45, suggesting a potential upside of 104.13%. Given ImmuCell's higher probable upside, equities research analysts clearly believe Aspira Women's Health is more favorable than ImmuCell.
ImmuCell has higher revenue and earnings than Aspira Women's Health. ImmuCell is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
ImmuCell has a net margin of -18.31% compared to ImmuCell's net margin of -163.95%. Aspira Women's Health's return on equity of -15.21% beat ImmuCell's return on equity.
ImmuCell received 108 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 27.08% of users gave Aspira Women's Health an outperform vote.
Summary
ImmuCell beats Aspira Women's Health on 11 of the 17 factors compared between the two stocks.
Get ImmuCell News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
